Fecal Anti-Gliadin Antibody

A stool panel that flags antibodies against gluten can feel like the answer to years of bloating, cramps, or loose stools. The difficulty is connecting that laboratory finding to a diagnosis. Fecal anti-gliadin antibody testing remains exploratory, and its value as an addition to standard celiac testing hasn't been established.

What the Stool Test Picks Up

Gliadin is a group of proteins in wheat gluten. Rye and barley contain related proteins that also trigger celiac disease. Anti-gliadin antibodies bind to gliadin, and antibodies produced within the intestine can pass into stool.

This test measures anti-gliadin antibodies in a stool sample using an immunoassay. An immunoassay detects a target through antibody-binding reactions. The catalog specifies an index result but doesn't identify the antibody class or whether the assay detects the secretory form of an antibody.

That missing detail matters when comparing evidence. Several published stool studies measured IgA or secretory IgA specifically. IgA is an antibody class found in blood and intestinal secretions. Findings from those studies provide related evidence, but their accuracy and response to diet cannot automatically be assigned to this assay.

The index uses the laboratory's own reporting scale. Its exact calculation depends on the assay, so it shouldn't be described as a particular ratio without the manufacturer's documentation. Index values from different stool tests aren't interchangeable, and they can't be converted into blood antibody results.

How Well Stool Antibodies Detect Celiac Disease

Celiac disease is an autoimmune condition in which eating gluten causes damage to the small intestine. Standard evaluation uses celiac-specific blood antibodies and, when indicated, intestinal biopsies. Stool anti-gliadin antibodies have not shown comparable diagnostic reliability.

A pediatric validation study compared commercial stool secretory IgA assays with intestinal biopsies in 20 children with celiac disease and 64 without it. These were different assays from the cataloged index test, so their performance figures describe those studied assays. With only 20 cases, the sensitivity figure is very imprecise.

A 2024 review found inconsistent results across stool antibody studies, each of which included only a few untreated patients. Some small adult studies reported higher fecal anti-gliadin IgA in untreated celiac disease, while other comparisons found no useful distinction. The studies used different assays, antibody classes, and sample-processing methods.

Antibody class changes the picture. In one adult study using extracts from 24-hour stool collections, anti-gliadin IgA was higher in untreated than treated celiac disease. Anti-gliadin IgM was raised in both groups, and IgG and IgE didn't separate them. Because the catalog doesn't name this assay's antibody class, it's unclear which of these patterns applies to your result.

Blood tissue transglutaminase IgA has a much stronger diagnostic evidence base. It measures antibodies against one of your own proteins involved in celiac disease. Its performance varies with the assay, gluten intake, and severity of intestinal damage.

Even the blood version of this antibody has been retired from celiac diagnosis. Current guidelines no longer recommend blood tests for antibodies against native gliadin, because tissue transglutaminase and deamidated gliadin peptide tests perform better.

What a Positive Result Can Support

A positive result indicates that the assay detected binding interpreted as anti-gliadin antibodies. Whether that finding explains your symptoms, reflects intestinal injury, or predicts a response to avoiding gluten remains uncertain. A laboratory flag alone doesn't establish celiac disease, wheat allergy, or non-celiac gluten sensitivity.

Older studies found associations between intestinal antibodies and celiac disease when fluid was sampled directly from the small intestine. Some antibody patterns also appeared in people with normal-looking biopsies. Those studies disagree about diet, too: one found small-intestinal anti-gliadin IgA negative in every child on a gluten-free diet, while another found the celiac-like antibody pattern in 16 of 23 people on the diet. Those findings concern intestinal fluid collected during a procedure, and they don't validate interpretation of a stool index.

Non-celiac gluten sensitivity has no validated diagnostic antibody test. A Japanese study found that blood anti-gliadin IgG had limited ability to separate people with suspected gluten sensitivity from controls. The comparison used clinical suspicion rather than a confirmed diagnosis, and it measured blood IgG rather than stool antibodies. Blood anti-gliadin IgG also turns up in celiac disease and irritable bowel syndrome, so a positive result isn't specific to gluten sensitivity.

Why Accurate Celiac Diagnosis Matters

Celiac disease often goes unrecognized. A population study involving nearly 13,000 adults in Norway estimated that three quarters of people with celiac disease were previously undiagnosed. This finding came from blood screening and intestinal assessment; it provides no evidence that stool antibody screening would find those cases.

First-degree relatives of someone with celiac disease and people with type 1 diabetes have higher odds of the condition. Selective IgA deficiency also matters. In one study of 126 children with this deficiency, 8.7% were diagnosed with celiac disease through IgG-based blood testing and biopsy. Other IgA-deficiency cohorts have reported figures from roughly 8% to 15%.

Some people have celiac disease despite negative blood antibodies. In records spanning 20 years at referral centers, comparing 84 adults with confirmed antibody-negative celiac disease with 2,084 antibody-positive cases, the antibody-negative group had about eleven times the hazard of complications and about twice the hazard of death. Most complications were a form of celiac disease that persists despite a gluten-free diet. After adjusting for other factors, being antibody-negative didn't independently predict death. These observational estimates describe confirmed disease in specialist populations, and they cannot be inferred from a stool antibody result.

When Results Can Be Misleading

• Assay and antibody-class differences: studies of stool IgA, secretory IgA, blood IgG, and blood antibodies to modified gliadin fragments concern different measurements. In one stool study, IgM anti-gliadin stayed high on a gluten-free diet while IgA fell. Their results don't establish the accuracy of this unspecified antibody-class index.
• Sample processing: stool water content, extraction, dilution, and storage can affect antibody recovery. Instructions for another stool IgA assay warn that diarrhea can mask increased antibody production. The size of this effect hasn't been established for this index assay.
• Limited interference information: the catalog doesn't provide assay-specific information about cross-reactivity or other substances that may affect binding. A result shouldn't be treated as proof of a disease-specific immune reaction.
• IgA deficiency: if the laboratory confirms that its assay measures IgA, reduced IgA production may limit antibody detection. A normal total IgA blood result still doesn't validate the stool assay.
• Changes in gluten intake: gluten restriction can reduce established celiac blood markers. Its effect on this particular stool index, including the timing and size of any change, hasn't been established. If the assay detects IgM or total antibodies, any fall on the diet is even less predictable.
• Unproven interpretation: neither a higher index nor a change over time has been validated as a measure of intestinal damage, symptom severity, or healing.

Limits of Serial Trending

There is no established amount of change in this index that separates ordinary variation from a meaningful change in health. Repeated measurements haven't been shown to improve diagnosis or document intestinal healing. Using the same laboratory may reduce differences between methods, but it doesn't resolve those limitations.